Research programme: liposome formulated therapeutics - Recoly
Alternative Names: Liposomal glucocorticoid - Recoly; NecLip-G-CSF; REC-200Latest Information Update: 16 Jul 2016
At a glance
- Originator Recoly
- Class Antirheumatics; Glucocorticoids; Granulocyte colony-stimulating factors
- Mechanism of Action Glucocorticoid receptor agonists; Granulocyte colony stimulating factor replacements; Nerve growth factor stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis; Stem cell mobilisation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Belgium (Parenteral, Liposomal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Belgium (Parenteral, Liposomal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stem-cell-mobilisation in Belgium (Parenteral, Liposomal)